IMPORTANT NOTICE FROM THE WORLD HEALTH ORGANIZATION CONCERNING THE BIOLOGICAL MATERIALS IN THIS SHIPMENT

Please share with the appropriate representative(s) of your institution

Acceptance of the biological materials in this shipment will entail certain obligations under the Pandemic Influenza Preparedness Framework, as detailed below.

Background
This shipment is made in connection with an international framework approved in May 2011 by the 194 Member countries of the World Health Organization (“WHO”). That international framework is called the “Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits” (the “PIP Framework”). Its objective is to “improve pandemic influenza preparedness and response, and strengthen the protection against pandemic influenza by improving and strengthening the WHO Global Influenza Surveillance and Response System (“WHO GISRS”). This is accomplished through, inter alia, the rapid, systematic and timely sharing by countries of their influenza viruses with human pandemic potential with the WHO GISRS, and the fair and equitable access by countries in need to vaccines and other benefits arising from such virus sharing (see PIP Framework, section 1(8) and section 2). Access to benefits is facilitated principally through two mechanisms: the “Standard Material Transfer Agreement 2” and the “Partnership Contribution”.

This Shipment
The materials contained in this shipment are known as “PIP biological materials” or “PIPBMs”. They are the result of sharing of influenza viruses by WHO Member countries with the WHO GISRS, as well as collaboration and significant work by many laboratories in the WHO GISRS. The PIBBM in this shipment are provided to your institution free of charge, subject to the following:

1) Agreement to conclude a ‘Standard Material Transfer Agreement 2’ (SMTA 2)
   • Under the PIP Framework, all non-GISRS entities that receive PIBBM must conclude an SMTA 2 with WHO. A model SMTA 2 is found at Annex 2 of the PIP Framework.
   • By accepting these materials, you recognize that in due course you will be contacted by WHO to discuss and conclude a Standard Material Transfer Agreement 2 (SMTA 2) under the PIP Framework.
   • Conclusion of an SMTA 2 will entail your institution’s selection of benefit-sharing commitments based on its nature and capacities. The model SMTA 2 in the PIP Framework identifies the benefit options from which your institution may choose.
   • After an SMTA 2 is concluded between your institution and WHO, and as long as it remains in force, your institution will be able to receive additional shipments of PIBBM.

1 To download a copy of the PIP Framework, see: http://www.who.int/influenza/pip/en/
2 See PIP Framework Section 4.3: “WHO GISRS” means the international network of influenza laboratories, coordinated by WHO, that conduct year-round surveillance of influenza, assessing the risk of pandemic influenza and assisting in preparedness measures. The WHO GISRS comprises National Influenza Centres, WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and Essential Regulatory Laboratories. «
3 See PIP Framework Section 4.1 for a full definition of PIBM.
4 Subject to the availability of funds at the shipping laboratory; the recipient may be requested to bear the shipping costs.
2) **Partnership Contribution**

By accepting these materials, you further recognize that you will be contacted by WHO to complete an annual ‘Partnership Contribution Questionnaire’. This Questionnaire is part of the process to implement the ‘Partnership Contribution’, a “sustainable and innovative financing mechanism” established by WHO Member States under PIP Framework section 6.14.

- The Questionnaire will be used to determine if your institution is an “influenza vaccine, diagnostic [or] pharmaceutical manufacturer using the Global Influenza Surveillance and Response System (GISRS).” (See Framework section 6.14.3)
- Under the PIP Framework, receipt of PIPBM constitutes use of GISRS and as such, based on the responses to the aforementioned Questionnaire, your institution may be identified as a Contributor to the PIP Partnership Contribution.

If you agree with the foregoing, there is nothing further to do at this time. If you do not agree with the foregoing, you must inform the shipping laboratory immediately and arrange for the return of the materials.

You may only further transfer the materials in this shipment if the prospective recipient has concluded an SMTA 2 with WHO or you have received authorization to do so from WHO.

You can find the full PIP Framework, as well as information and background materials at [http://www.who.int/influenza/pip/en/](http://www.who.int/influenza/pip/en/). If you have any questions regarding this notice, please do not hesitate to contact the PIP Framework Secretariat at pipframework@who.int.

December 2014